Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Balsalazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.51 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.51 |
| ▸ | SIRT5 | Q9NXA8 | 5/20 | 1.00 |
| ▸ | NME4 | O00746 | 3/20 | 1.00 |
| ▸ | GCDH | Q92947 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | AVPR2 | P30518 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | AVPR1A | P37288 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | BLVRB | P30043 | 2/20 | 0.59 |
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Balsalazide SCHEMBL138311 | 1.00 | SIRT5 (1.00) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL3267109 | 1.00 | SIRT5 (1.00) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL29377041 | 1.00 | SIRT5 (1.00) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL7908058 | 0.99 | SIRT5 (0.97) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL28818120 | 0.99 | SIRT5 (0.97) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL134019 | 0.99 | SIRT5 (0.97) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL5598491 | 0.99 | SIRT5 (0.97) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL133200 | 0.97 | SIRT5 (0.95) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL20184744 | 0.93 | SIRT5 (0.87) | SIRT5NME4GCDHTDP1HRH3 | |
| Balsalazide SCHEMBL17392780 | 0.93 | SIRT5 (0.87) | SIRT5NME4GCDHTDP1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 9137 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| EP-4705511-A1 | DNA METHYLATION-BASED ALGORITHM TO DIAGNOSE IRRITABLE BOWEL SYNDROME AND OTHER GI CONDITIONS | The Regents of the University of California (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| EP-4687850-A1 | ORAL DRUG DOSAGE FORMS FOR COLON DELIVERY AND METHODS OF USE AND MAKING THEREOF | Triastek, Inc. (CN) | 2026-02-11 | — | — | EP | claimed |
| EP-4689191-A2 | METHODS OF CLASSIFYING AND TREATING INFLAMMATORY BOWEL DISEASE | Baylor College of Medicine (US) | 2026-02-11 | — | — | EP | claimed |
| US-20260007611-A1 | ULTRASOUND RESPONSIVE NANOCLUSTER FOR CANCER TREATMENT AND METHOD FOR MANUFACTURING THE SAME | INDUSTRY UNIV COOPERATION FOUNDATION YEUNGNAM UNIV (KR) | 2026-01-08 | — | — | US | claimed |
| WO-2025245006-A1 | EXHALED BREATH OF VOLATILE ORGANIC COMPOUNDS FOR IBD DIAGNOSIS AND MANAGEMENT | THE CLEVELAND CLINIC FOUNDATION (US) | 2025-11-27 | — | — | WO | claimed |
| US-12473370-B2 | TL1A associated antibody compositions and methods of use | Absci Corporation (US) | 2025-11-18 | — | — | US | claimed |
| WO-2000069255-A1 | ANTI-INFLAMMATORY THERAPY FOR INFLAMMATORY MEDIATED INFECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-11-23 | — | — | WO | claimed |
| WO-2000056772-A1 | HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING | KNOLL GMBH (DE) | 2000-09-28 | — | — | WO | claimed |
| WO-2000045803-A2 | USE OF 5-AMINOSALICYLATES AS ANTIMICROBIAL AGENTS | CEDARS-SINAI MEDICAL CENTER (US) | 2000-08-10 | — | — | WO | claimed |
| EP-0980246-A1 | THERAPY FOR CONSTIPATION | BORODY, Thomas Julius (AU) | 2000-02-23 | — | — | EP | claimed |
| WO-2000004924-A1 | COMPOSITION AND PHARMACEUTICAL DOSAGE FORM FOR COLONIC DRUG DELIVERY USING POLYSACCHARIDES | SAMYANG CORPORATION (KR) | 2000-02-03 | — | — | WO | claimed |
| EP-0974344-A2 | Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides | Samyang Corporation (KR) | 2000-01-26 | — | — | EP | claimed |
| US-5905073-A | ANTICARCINOGENIC AGENTS | SALIX PHARMACEUTICALS, INC. (US) | 1999-05-18 | — | — | US | claimed |
| WO-1998050043-A1 | NOVEL THERAPY FOR CONSTIPATION | BORODY THOMAS J (AU) | 1998-11-12 | — | — | WO | claimed |
| CN-1140994-A | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents | SALIX PHARMACEUTICALS INC (US) | 1997-01-22 | — | — | CN | claimed |
| US-5498608-A | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents | SALIX PHARMACEUTICALS (US) | 1996-03-12 | — | — | US | claimed |